IRLAB Therapeutics AB
STO:IRLAB A

Watchlist Manager
IRLAB Therapeutics AB Logo
IRLAB Therapeutics AB
STO:IRLAB A
Watchlist
Price: 6.78 SEK -1.31%
Market Cap: 351.1m SEK

Intrinsic Value

IRLAB A's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one IRLAB A stock under the Base Case scenario is 16.49 SEK. Compared to the current market price of 6.78 SEK, IRLAB Therapeutics AB is Undervalued by 59%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

IRLAB A Intrinsic Value
16.49 SEK
Undervaluation 59%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
IRLAB Therapeutics AB

Valuation History Unavailable

Historical valuation for IRLAB A cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%
Compare IRLAB A to

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about IRLAB A?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about IRLAB Therapeutics AB
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
IRLAB Therapeutics AB

Current Assets 104.2m
Cash & Short-Term Investments 88.6m
Receivables 15.6m
Other Current Assets 1k
Non-Current Assets 55.5m
PP&E 8.7m
Intangibles 46.9m
Efficiency

Free Cash Flow Analysis
IRLAB Therapeutics AB

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
IRLAB Therapeutics AB

Revenue
99m SEK
Cost of Revenue
-132.2m SEK
Gross Profit
-33.2m SEK
Operating Expenses
-32.9m SEK
Operating Income
-66.1m SEK
Other Expenses
-12m SEK
Net Income
-78.1m SEK
Fundamental Scores

IRLAB A Profitability Score
Profitability Due Diligence

IRLAB Therapeutics AB's profitability score is 10/100. The higher the profitability score, the more profitable the company is.

10/100
Profitability
Score

IRLAB Therapeutics AB's profitability score is 10/100. The higher the profitability score, the more profitable the company is.

IRLAB A Solvency Score
Solvency Due Diligence

IRLAB Therapeutics AB's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
48/100
Solvency
Score

IRLAB Therapeutics AB's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IRLAB A Price Targets Summary
IRLAB Therapeutics AB

There are no price targets for IRLAB A.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

IRLAB Therapeutics AB
does not pay dividends
Shareholder Yield

Current shareholder yield for IRLAB A is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

IRLAB A Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one IRLAB A stock?

The intrinsic value of one IRLAB A stock under the Base Case scenario is 16.49 SEK.

Is IRLAB A stock undervalued or overvalued?

Compared to the current market price of 6.78 SEK, IRLAB Therapeutics AB is Undervalued by 59%.

Back to Top